Fig. 6 | Scientific Reports

Fig. 6

From: Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment

Fig. 6

Metabolites from (a) hαCGRP8-37S19K-C20DA-γGlu and (b) hαCGRP8-37N25K-C20DA-γGlu. K* refers to the lysine residue where the C20DA-γGlu is positioned. Abundance was estimated as the ratio of metabolite-EIC relative to EIC of the intact peptide. For each timepoint, the most abundant metabolites are highlighted by a progressive increase in colour intensity. Results are presented as mean of n = 2.

Back to article page